The new antimicrobial agents

References

• Mehtar S, Croft RJ, Hilas A. A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections. J Antimicrob Chemother 1986: 17(3): 389–96
   PubMed Web of Science ®Google Scholar
• Davies BI, Maesen FP, Jerons S, et al. Combination of sulbactam pivoxyl and bacampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1982: 10(5): 445–52
   PubMed Web of Science ®Google Scholar
• Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985: 161(4): 303–7
   PubMedGoogle Scholar
• Gunning J. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease. Drugs 1986: 31(Suppl 2): 14–7
   PubMed Web of Science ®Google Scholar
• Reinhardt JF, Johnston L, Ruane P, et al. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections. Rev Infect Dis 1986: 8(Suppl 5): S569–75
   PubMedGoogle Scholar
• Iravani A, Richard GA, Johnson D, et al. A double-blind, multicenter, comparative study of the safety and efficacy of Cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients. Am J Med 1988: 85(3A): 17–23
   PubMed Web of Science ®Google Scholar
• McCracken GH Jr. Selection of antimicrobial agents for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987: 6(10): 985–8
   PubMed Web of Science ®Google Scholar
• Kenna MA, Bluestone CD, Fall P, et al. Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children. Pediatr Infect Dis J 1987: 6(10): 992–6
   PubMed Web of Science ®Google Scholar
• Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of Cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med 1988: 85(3A): 6–13
   PubMed Web of Science ®Google Scholar
• Swabb EA, Jenkins SA, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections. Rev Infect Dis 1985: 7(Suppl 4): S772–7
   PubMedGoogle Scholar
• Swabb EA, Cone CO, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections. Rev Infect Dis 1985: 7 (Suppl 4): S675–8
   PubMedGoogle Scholar
• Schentag JJ, Van AJ, Winslade NE, et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985: 78(2A): 34–41
   PubMed Web of Science ®Google Scholar
• Scully BE, Henry SA. Clinical experience with aztreonam in the treatment of gram-negative bacteremia. Rev Infect Dis 1985: 7(Suppl 4): S789–93
   PubMedGoogle Scholar
• Birolini D, Moraes MF, de Souza OS. Aztreonam plus clindamycin vs tobramycin plus clindamycin for the treatment of intraabdominal infections. Rev Infect Dis 1985: 7(Suppl 4): S724–8
   PubMedGoogle Scholar
• Chambers ST. Carbapenems, monobactams and quinolones. N Z Med J 1989: 102(860): 6–7 [erratum, N Z Med J 1989; 102(868): 262]
   PubMed Web of Science ®Google Scholar
• Adkinson NF Jr, Saxon A, Spence MR, et al. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis 1985: 7(Suppl 4): S613–21
   PubMedGoogle Scholar
• Jones PG, Bodey GP, Swabb EA, et al. Effect of aztreonam on throat and stool flora of cancer patients. Antimicrob Agents Chemother 1984: 26(6): 941–3
   PubMed Web of Science ®Google Scholar
• Quinn JP, Studemeister AE, DiVincenzo CA, et al. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988: 10(4): 892–8
   PubMedGoogle Scholar
• Calandra GB, Brown KR, Grad LC, et al. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med 1985: 78(6A): 73–8
   PubMed Web of Science ®Google Scholar
• Acar JF. Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience. Rev Infect Dis 1985: 7(Suppl 3): S513–7
   PubMedGoogle Scholar
• Bodey GP, Alvarez ME, Jones PG, et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986: 30(2): 2114
   Google Scholar
• Fass RJ, Freimer EH, McCloskey RV. Treatment of skin and soft tissue infections with imipenem/cilastatin, Am J Med 1985: 78(6A): 110–2
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Fant WK, Rivera JO, et al. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985: 78(6A): 85–91
   PubMed Web of Science ®Google Scholar
• Sweet RL. Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience. Rev Infect Dis 1985: 7(Suppl 3): S522–7
   PubMedGoogle Scholar
• Weder HM, Finegold SM. Impact of imipenem/cilastatin therapy on normal fecal flora. Am J Med 1985: 78(6A): 41–6
   Web of Science ®Google Scholar
• Rowen RC, Michel DJ, Thompson JC. Norfloxacin: clinical pharmacology and clinical use. Pharmacotherapy 1987: 7(4): 92–110
   PubMed Web of Science ®Google Scholar
• Rowen RC, Mullenix TA, Arroyo JC, et al. Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy. Drug Intell Clin Pharm 1988: 22(10): 773–6
   PubMedGoogle Scholar
• Vogel R, Deaney NB, Round EM, et al. Norfloxacin, amoxicillin, cotrimoxazole and nalidixic acid: a summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. J Antimicrob Chemother 1984: 13(Suppl B): 113–20
   PubMedGoogle Scholar
• Sabbaj J, Hoagland VL, Shih WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 1985: 27(3): 297–301
   PubMed Web of Science ®Google Scholar
• Leigh DA, Smith EC, Marriner J. Comparative study using norfloxacin and amoxicillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother 1984: 13(Suppl B): 79–83
   PubMedGoogle Scholar
• Crider SR, Colby SD, Miller LK, et al. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med 1984: 311(3): 137–40
   PubMed Web of Science ®Google Scholar
• Kaplowitz LG, Vishniavsky N, Evans T, et al. Norfloxacin in the treatment of uncomplicated gonococcal infections. Am J Med 1987: 82(6B): 35–9
   PubMed Web of Science ®Google Scholar
• LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988: 8(1): 3–33
   PubMed Web of Science ®Google Scholar
• Gerding DN, Hitt JA. Tissue penetration of the new quinolones in humans. Rev Infect Dis 1989: 11(Suppl 5): S1046–57
   PubMedGoogle Scholar
• Kobayashi H. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. Am J Med 1987: 82(4A): 169–73
   PubMed Web of Science ®Google Scholar
• Eron LJ. Therapy of skin and skin structure infections with ciprofloxacin. Am J Med 1987: 82 (Suppl 4A): 224–6
   PubMed Web of Science ®Google Scholar
• Neu HG. Clinical use of the quinolones. Lancet 1987: 2(8571): 1319–22
   PubMed Web of Science ®Google Scholar
• Gasser TC, Graversen PH, Madsen PO. Treatment of complicated urinary tract infections with ciprofloxacin. Am J Med 1987: 82(Suppl 4A): 278–9
   Web of Science ®Google Scholar
• Pichler HE, Diridl G, Stickler K, et al. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987: 82(4A): 329–32
   PubMed Web of Science ®Google Scholar
• Wollschlager CM, Raoof S, Khan FA, et al. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. Am J Med 1987: 82(4A): 164–8
   PubMed Web of Science ®Google Scholar
• Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxicillin. J Antimicrob Chemother 1986: 18(Suppl D): 133–8
   PubMedGoogle Scholar
• Bantz PM, Grote J, Peters-Haertel W, et al. Low-dose ciprofloxacin in respiratory tract infections: randomized comparison with doxycycline in general practice. Am J Med 1987: 82(Suppl 4A): 208–10
   Web of Science ®Google Scholar
• Lode H, Wiley R, Hoffken G, et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 1987: 31(10): 1491–6
   PubMed Web of Science ®Google Scholar
• Neu HC. Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis 1989: 11(Suppl 5): S1025–35
   PubMedGoogle Scholar
• Weidner W, Schiefer HG, Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin: results of a one-year follow-up study. Am J Med 1987: 82(4A): 280–3
   PubMed Web of Science ®Google Scholar
• Ying LS, Johnson CA Ciprofloxacin-induced interstitial nephritis. Clin Pharm 1989: 8(7): 518–21
   PubMedGoogle Scholar